![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=1050961973852737)
glp-1 receptor agonists should be avoided in patients with
Shipping Estimate
glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://www.frontiersin.org/api/ipx/w=1200&f=png/https://www.frontiersin.org/files/Articles/721135/fendo-12-721135-HTML/image_m/fendo-12-721135-g001.jpg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://www.frontiersin.org/files/Articles/738848/xml-images/fendo-12-738848-g001.webp)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://www.datocms-assets.com/92605/1713817602-featured-image.png?auto=format&q=65)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://lookaside.fbsbx.com/lookaside/crawler/media/?media_id=885143080705603)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://www.teachmepharmacy.info/wp-content/uploads/2025/10/AdobeStock_577004646-scaled.jpeg)
![glp-1 receptor agonists should be avoided in patients with Weight-Loss Medication Glucagon-like peptide-1 (GLP-1) (semaglutide [Wegovy, Ozempic, Rybelsus]) and dual incretin agonists (tirzepatide [Zepbound, Mounjaro]) are popular treatments for obesity. The authors discuss the kind of Frontiers | GLP-1 Receptor Agonists:](https://ars.els-cdn.com/content/image/1-s2.0-S2589004226010758-fx1.jpg)
![Cao Ren, Wei Commander [Portal Three Kingdoms] SM214](https://cdn.shopify.com/s/files/1/0581/0284/1476/products/c1f479e4-9174-556b-971e-0546f2c48ef7.jpg?v=1649225620)
![Imperious Perfect [Champs and States] Beast-Warrior](https://cdn.shopify.com/s/files/1/0581/0284/1476/products/d3bcdc4b-8d64-58a0-b65d-50e1e698ab03.jpg?v=1649225790)